CoChat

Quercetin Phytosome® as a potential candidate for managing COVID-19

DI PIERRO, Francesco, KHAN, Amjad, BERTUCCIOLI, Alexander, MAFFIOLI, Pamela, DEROSA, Giuseppe, KHAN, Saeed, KHAN, Bilal A., NIGAR, Roohi, UJJAN, Ikram, DEVRAJANI, Bikha R. · 2021 · Minerva Gastroenterology
Cited by 41

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

When looking for new antiviral compounds aimed to counteract the COVID-19, a disease caused by the recently identified novel Coronavirus (SARS-CoV-2), the knowledge of the main viral proteins is fundamental. The major druggable targets of SARS-CoV-2 include 3-chymotrypsin-like protease (3CLpro), papain-like protease (PLpro), RNA-dependent RNA polymerase, and spike (S) protein. Molecular docking studies have highlighted that quercetin, a natural polyphenol belonging to the flavonol class, inhibits 3CLpro, PLpro and S proteins. Biophysical technics have then very recently confirmed that quercetin is reasonably a potent inhibitor of 3CLpro. The likely antiviral properties of quercetin are anyway challenged by its very poor oral bioavailability profile and any attempt to overcome this limit should be welcome. A phospholipid delivery form of quercetin (Quercetin Phytosome®) has been recently tested in humans to evaluate a possible improvement in oral bioavailability. After hydrolysis of the conjugated form (mainly glucuronide) of quercetin found in human plasma, the pharmacokinetics results have demonstrated an increased bioavailability rate by about 20-fold for total quercetin. It has been also observed that the presence of specific glucuronidase could yield free systemic quercetin in human body. Taking also into considerations its anti-inflammatory and thrombin-inhibitory actions, a bioavailable form of quercetin, like Quercetin Phytosome®, should be considered a possible candidate to clinically face COVID-19.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.23736/s2724-5985.20.02771-3

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 36

  1. Kannan S, 2020, COVID-19 (Novel Coronavirus 2019) - recent trends, Eur Rev Med Pharmacol Sci, 24, 2006
  2. 10.4103/0973-7847.194044 · DOI · Paper page
  3. 10.1016/j.jcrc.2020.03.005 · DOI · Paper page
  4. 10.5582/bst.2020.03072 · doi:10.5582/bst.2020.03072
  5. 10.1002/jmv.25729 · DOI · Paper page
  6. Khamitov RA, 2008, [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures], Vopr Virusol, 53, 9
  7. 10.5582/bst.2020.01020 · DOI · Paper page
  8. 10.1016/j.ijsu.2020.03.036 · doi:10.1016/j.ijsu.2020.03.036
  9. 10.1016/j.apsb.2020.02.008 · DOI · Paper page
  10. 10.1002/jmv.25761 · DOI · Paper page
  11. 10.1016/j.joim.2020.02.005 · DOI · Paper page
  12. 10.1038/nprot.2016.051 · DOI · Paper page
  13. 10.1021/acs.jcim.7b00341 · DOI · Paper page
  14. 10.1016/j.ctim.2019.102294 · DOI · Paper page
  15. Smith M, 2020, Repurposing therapeutics for COVID-19: supercomputer-based docking to the SARS-CoV-2 viral spike protein and viral spike protein-human ACE2 interface, ChemRxiv, ahead of print
  16. 10.1016/j.bcp.2020.114123 · DOI
  17. Pandey P, 2020, Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development, J Biomol Struct Dyn, 1, 10.1080/07391102.2020.1796811 · DOI · Paper page
  18. Khaerunnisa S, 2020, Potential inhibitor of COVID-19 main protease (Mpro) from several medicinal plant compounds by molecular docking study, Preprints, ahead of print
  19. 10.1016/j.ijbiomac.2020.07.235 · DOI · Paper page
  20. 10.1016/j.ijpharm.2010.11.009 · DOI · Paper page
  21. 10.1016/j.tifs.2016.07.004 · DOI · Paper page
  22. 10.1007/s13318-018-0517-3 · DOI · Paper page
  23. 10.1079/BJN20061809 · DOI · Paper page
  24. 10.1093/ajcn/79.5.727 · DOI · Paper page
  25. 10.3390/nu9020111 · DOI
  26. 10.1007/s00394-003-0397-3 · DOI · Paper page
  27. 10.1371/journal.pone.0032673 · DOI
  28. Shimoi K, 2001, Deglucuronidation of a flavonoid, luteolin monoglucuronide, during inflammation, Drug Metab Dispos, 29, 1521
  29. 10.1016/j.abb.2008.03.004 · DOI · Paper page
  30. 10.2174/138161210790112674 · doi:10.2174/138161210790112674
  31. 10.1016/S0140-6736(20)30937-5 · DOI · Paper page
  32. 10.1128/AAC.00530-20 · DOI
  33. 10.1016/j.thromres.2010.08.006 · doi:10.1016/j.thromres.2010.08.006
  34. 10.1016/j.phrs.2010.05.001 · DOI · Paper page
  35. 10.1186/s13020-020-00317-x · DOI · Paper page
  36. 10.1002/ptr.6887 · DOI · Paper page

Cited by

See all 41

Metadata

Authors
DI PIERRO, F., KHAN, A., BERTUCCIOLI, A., MAFFIOLI, P., DEROSA, G., KHAN, S., KHAN, B. A., NIGAR, R., UJJAN, I., & DEVRAJANI, B. R.
Venue
Minerva Gastroenterology
Published
2021-05
Volume
67
Issue
2
Pages
190-195
ISSN
  • 0026-4776 (ISSN-L)
  • 2724-5985
  • 2724-5365
OpenAlex
W3091043182
Cited by
41
References
3
FWCI
4.14
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Quercetin Phytosome® as a potential candidate for managing COVID-19. https://app.cochat.ai/papers/10.23736/s2724-5985.20.02771-3
The paper
DI PIERRO, F., KHAN, A., BERTUCCIOLI, A., MAFFIOLI, P., DEROSA, G., KHAN, S., KHAN, B. A., NIGAR, R., UJJAN, I., & DEVRAJANI, B. R. (2021). Quercetin Phytosome® as a potential candidate for managing COVID-19. Minerva Gastroenterology. https://doi.org/10.23736/s2724-5985.20.02771-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.